CORE 2 --REAGENT EVALUATION, PRODUCTION AND PERMIT

Core2的作用有三个方面：1)临床前评估和分析药物、多肽、单抗及其衍生结构和激活的免疫细胞在毒性、稳定性、体内定位和治疗效果方面的临床应用，这些在该孢子的项目1、2和3中产生并在临床上实施；2)生产临床级别的单抗试剂；以及3)制备和提交研究性新药(IND)，允许申请所有具有潜在临床用途的试剂。这一核心提供了从BASE到临床给药的连续统一体，并确保正在开发的试剂的有序进展和质量控制，这是我们目前在第一阶段和第二阶段临床试验中成功开发和实施MAB试剂的特点。核心2的功能/特定目标如下：具体目标1.对完整的、工程的、结合的和修饰的单抗和免疫反应批次的前临床评估，在免疫活性和无性系啮齿动物肿瘤异种移植模型中，包括皮下和颅内模型中，目前在核心3正在研究的单抗和免疫反应批次的体内稳定性、定位和疗效。具体目标2.对衍生多肽、药物和其他部分在动物模型中的体内稳定性、定位和治疗效果进行临床前分析，如目标1中所述，用于项目1、2和3中确定的任何有希望的试剂。 具体目标3.所有试剂(药物、多肽、单抗、 和衍生结构)在项目1、2和3中产生，并在该孢子的核心3中进行调查。A.通过对细菌、真菌、病毒、热原和DNA污染的所有分析以及体内的一般安全性测试(核心3免疫试剂)的性能或合同进行质量控制，b.对药物、多肽、单抗毒素结合物、核素单抗结合物及其衍生物以及动物模型中的效应细胞进行毒性测试和分析(正常和自闭性啮齿类动物；项目1、2和3；核心3)。C测定在裸鼠和正常大鼠和小鼠模型系统(皮下、颅内、中枢神经系统肿瘤)中所有无毒性、最大稳定性和治疗效果的物质的最大耐受量(MTD) 异种移植：项目1和2)。具体目标4.临床级试剂的生产：生产足够数量的临床级单抗、抗体片段、构建体和结合物，用于进行临床试验。项目1中的小分子抑制剂将外包给GMP生产商或NCI RAIDs计划。具体目标5.为项目1、2和3中开发的所有拟议疗法准备和提交IND许可证申请。作为临床前开发核心，核心2对项目1、2和3以及核心1和3具有基本的支持功能。

The role of Core 2 is threefold: 1) the preclinical evaluation and analysis of drugs, peptides, MAbs and derived constructs, and activated immune cells for clinical application in terms of toxicity, stability, in vivo localization and therapeutic effect, generated in Projects 1, 2, and 3 of this SPORE and implemented clinically in Core 3; 2) the production of clinical grade MAb reagents; and 3) the preparation and submission of Investigational New Drug (IND) permit applications for all reagents of potential clinical utility. This Core provides a continuum from bench to clinical administration and assures the orderly progression and quality control of reagents in development that have characterized the development and implementation of our currently successful MAb reagents in Phase I and II clinical trials. The Functions/Specific Aims of Core 2 are as follows: Specific Aim 1. Pro-clinical evaluation of intact, engineered, conjugated, and modified constructs of MAbs and immunoreagent batches currently under investigation in Core 3 of this SPORE in terms of in vivo stability, localization, and therapeutic effect in immunocompetent and athymic rodent tumor xenograft models, including subcutaneous and intracranial models. Specific Aim 2. Pro-clinical analysis of derived peptides, drugs, and other moieties in terms of in vivo stabality, localization, and therapeutic effect in animal models as described in Aim 1 for any reagents of promise identified in Projects 1, 2, and 3. Specific Aim 3. Pro-clinical evaluation and quality certification of all reagents (drug, peptide, MAb, and derived constructs) generated in Projects 1, 2, and 3 and under investigation in Core 3 of this SPORE. a. Quality control by performance of, or contract for, all assays for bacterial, fungal, viral, pyrogen, and DNA contamination, and general safety tests in vivo (Core 3 immunoreagents), b. Toxicity testing and analysis of drug, peptide, MAb-toxin conjugates, nuclide-MAb conjugates and their derivatives, and effector cells in animal models (normal and athymlc rodents; Projects 1, 2 and 3; Core 3). c Determination of the maximum tolerated doses (MTD) for all substances showing no toxicity and maximal stability and therapeutic effect in athymic and normal rat and mouse model systems (subcutaneous, intracranial, CNS tumor xenografts: Projects 1 and 2). Specific Aim 4. Production of clinical grade reagents: Production of clinical grade MAb, antibody fragments, constructs, and conjugates in sufficient quantity for clinical trials conducted m Core 3. Small molecule inhibitors from Project 1 will be contracted out to GMP producers or the NCI RAID Program. Specific Aim 5. Preparation and submission of IND permit applications for all proposed therapies developed in Projects 1, 2, and 3. As the pre-clinical development Core, Core 2 has fundamental support functions for Projects 1, 2, and 3, and Cores 1 and 3.